November 7, 2018

Secretary of Health Alex Azar U. S. Department of Health and Human Services 200 Independence Avenue, S.W. Washington, D.C. 20201

Dear Secretary Azar,

We are writing as current and former members of the Chronic Fatigue Syndrome Advisory Committee (CFSAC), as biomedical researchers and clinicians with expertise in the disease Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), and as ME/CFS patient organizations to voice our concerns with HHS's decision to disband the CFSAC. We are calling for CFSAC to be immediately reinstated.

The 2015 report by the National Academy of Medicine (NAM) stated that ME/CFS "is a serious, chronic, complex, and multisystem disease that frequently and dramatically limits the activities of affected patients." NAM noted that ME/CFS affects 1-2.5M Americans of all genders, ages, races, and ethnic groups. It results in more functional impairment than a number of other chronic diseases with many patients unable to work and costs the economy \$17-24B annually in direct medical expenditures and lost productivity. NAM found, "remarkably little research funding," a "paucity of research" outside the fields of psychiatry and psychology, and a healthcare profession who have been persuaded that ME/CFS is a psychological problem. Further, NAM also notes a lack of diagnostics and FDA-approved treatments and a medical community that views the disease negatively, expresses hostility and disbelief to patients, and recommends treatments that can exacerbate their symptoms. This situation has persisted for the last three decades.

During its 15-year tenure, CFSAC repeatedly recommended that HHS address these issues. CFSAC's concerns were reiterated in HHS's own reports and in the NAM report. But the vast majority of those recommendations were not enacted by HHS and little changed.

Following the 2015 NAM report, co-sponsored by HHS and the Social Security Administration, and NIH's 2015 Pathways to Prevention report, the situation is just beginning to improve. NIH has begun to invest in research programs. The CDC has updated its website with more accurate information. A few major academic centers have begun to research the disease.

But funding still remains far below that of other similarly disabling diseases. The breadth and volume of research being conducted lags far behind that necessary to deliver urgently needed diagnostics and treatments. Little is known about the natural history of the disease and nothing about how to prevent it. There exist only a dozen or so clinical experts nationwide, a number of whom are reaching retirement age while other medical providers still either doubt the disease is real or lack the knowledge to provide appropriate patient-care. Patients struggle to get even the most basic treatment.

These outstanding needs – "research on diagnosis, treatment and management of ME/CFS", "inform…health care professionals", "partnerships to improve the quality of life of ME/CFS patients" – comprise the Duties outlined in CFSAC's Charter. CFSAC's work is not done. The very recent progress is still precarious, tentative, and has not yet made a difference in patient care or outcomes.

In the last two years, CFSAC has begun to establish productive, collaborative partnerships across the ME/CFS community, HHS agencies, and other Departments including the Social Security Administration, and the recently added Department of Defense and the Veterans' Administration. While not a member, the Department of Education was also an active participant. CFSAC's current workgroups had been focused on medical education, engaging pharmaceutical companies to stimulate treatment trials, and promoting awareness and education in schools. These efforts were all cut short when CFSAC was dissolved.

There is no other entity in the U.S. capable of advancing such broad-based engagement and collaborations across such diverse areas of need. Given CFSAC's unique role and the magnitude and urgency of persisting needs, we believe it is shortsighted to dissolve CFSAC at this critical time.

We respectfully request CFSAC's immediate reinstatement with the full constituency that existed when it was disbanded. We look forward to your response.

Respectfully,

Current CFSAC members (As of September 2018)

Dr. Faith Newton, (CFSAC Chair) Professor of Education Delaware State University Dover, Delaware

Lucinda Bateman, MD Medical Director Bateman Horne Center Salt Lake City, Utah

Alisa Erika Koch, MD, PhD

Jose G. Montoya, MD, FACP, FIDSA Professor of Medicine Division of Infectious Diseases and Geographic Medicine Stanford University School of Medicine Stanford, California

Donna Pearson

Amrit Shahzad, MBBS, MBA

Ben HsuBorger CFSAC Liaison Member for MEAction

Courtney Miller CFSAC Liaison Member for Simmaron Research

Terri L. Wilder, MSW CFSAC Liaison Member for MEAction

Leah Williams, PhD CFSAC Liaison Member for Massachusetts ME/CFS & FM Association

Former CFSAC Members

Dane Cook Professor University of Wisconsin – Madison Department of Kinesiology Madison, Wisconsin

Kenneth J. Friedman, PhD Associate Professor of Physiology and Pharmacology (retired) New Jersey Medical School University of Medicine and Dentistry of New Jersey Newark, New Jersey

Carol Head CFSAC Liaison Member for Solve ME/CFS Initiative President, Solve ME/CFS Initiative Los Angeles, California

Leonard A. Jason, PhD Professor of Psychology DePaul University Chicago, Illinois

Nancy Klimas MD Director, Institute for Neuro-Immune Medicine Nova Southeastern University Director, Miami VA Medical Center GWI and CFS/ME Program Miami, Florida

Steven P. Krafchick MPH, JD Treasurer, International Association for Chronic Fatigue Syndrome/Myalic Encephalomyelitis Private Law Practice Legal Services for Injured and Disabled People Seattle, Washington

Charles W. Lapp, MD Medical Director Hunter-Hopkins Center, PLLC Charlotte, North Carolina

Susan Levine, MD Researcher and Clinician, Private Practice New York, New York Visiting Fellow, Cornell University Ithaca, New York

James M. Oleske, MD, MPH François-Xavier Bagnoud Distinguished Professor of Pediatrics Senator of RBHS Research Centers, Bureaus, and Institutes Director, Division of Pediatrics Allergy, Immunology & Infectious Diseases Department of Pediatrics, Rutgers - New Jersey Medical School, Newark, New Jersey

Christopher R. Snell, PhD Scientific Director WorkWell Foundation Ripon, California

Staci Stevens, MA Exercise Physiologist Founder, Workwell Foundation Ripon, California

Other Researchers and Clinicians

James N. Baraniuk, MD Professor of Medicine Georgetown University Washington, DC Lily Chu, MD, MSHS Independent Researcher Burlingame, California

Janet L Dafoe, PhD Child Psychologist in Private Practice Palo Alto, California

Todd E. Davenport, PT, DPT, MPH, OCS Professor & Program Director University of the Pacific Thomas J. Long School of Pharmacy & Health Sciences Department of Physical Therapy Stockton, California

Ronald W. Davis, PhD Professor of Biochemistry and Genetics Stanford University Stanford, California

Lucy Dechene, PhD Professor of Mathematics (retired) Fitchburg State University Fitchburg, Massachusetts

Alan Gurwitt, MD Clinician in Private Practice (retired) Associate Clinical Professor Yale Child Study Center (retired) New Haven, Connecticut Associate Clinical Professor University of Connecticut Department of Psychiatry (retired) Storrs, Connecticut Lecturer, Harvard Medical School (retired) Boston, Massachusetts

Jon D. Kaiser, MD Clinical Faculty Department of Medicine University of California, San Francisco San Francisco, California

David L. Kaufman, MD Center for Complex Diseases Mountain View, California Member, The ME/CFS Collaborative Research Center at Stanford Palo Alto, California

Richard Podell, MD, MPH Clinical Professor, Department of Family Medicine Rutgers-Robert Wood Johnson Medical School New Brunswick, New Jersey

Peter C. Rowe, MD Professor of Pediatrics Johns Hopkins University School of Medicine Baltimore, Maryland

J. Mark VanNess, Ph.D. Professor of Health and Exercise Science University of the Pacific Stockton, California Workwell Foundation Ripon, California

Sadie Whittaker, PhD Chief Scientific Officer Solve ME/CFS Initiative Los Angeles, California

ME/CFS Patient Organizations

American ME and CFS Society Massachusetts

Massachusetts ME/CFS & FM Association Massachusetts

#MEAction California

Minnesota ME/CFS Alliance Minnesota

Open Medicine Foundation California

Pandora Org. Michigan Simmaron Research Foundation Nevada

Solve ME/CFS Initiative California

Wisconsin ME and CFS Association Wisconsin

CC:

Assistant Secretary for Health Brett P. Giroir, M.D.